RESEARCH
Researchers across labs and disciplines at ISB, along with the global scientific community at large, are working to uncover the secrets behind COVID-19 and SARS-CoV-2, the virus that causes the disease.
RESEARCH
Research suggests that it may be possible to eliminate the correlation between age and diseases. ISB is working to leverage systems biology approaches to understand the mechanistic links among the processes that accompany and/or lead to aging.
PHILANTHROPY
We are a nonprofit scientific research organization dedicated to shifting the health care model from treating sickness to fostering wellness.
You are committed to a better future, ISB is here to make that a reality.
RESEARCH
ISB and our collaborative network of partners is pioneering a multimodal approach that combines personal data, lifestyle factors, cognitive training and systems medicine, and is rigorously testing these new approaches in clinical trials. This approach is critical to prevent, slow, and even reverse many neurological conditions before they become irreversible.
From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2022-2023 academic year, we will highlight some of the top projects the team is working on.
High school students Ashwin Mukherjee and Rohan Chanani worked with ISB Research Scientist Dr. Jacob Valenzuela on a project to build a machine learning algorithm to count algal cells from microscope images taken from a cell phone. In April, the team was recognized as champions in the DOE-sponsored AlgaePrize competition.
This essay published by The Wall Street Journal is adapted from “The Age of Scientific Wellness,” the new book by Dr. Lee Hood, co-founder and professor of the Institute for Systems Biology, and Dr. Nathan Price, chief science officer of Thorne HealthTech.
In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.
